Search research articles
Contact Us
Filters
Showing results (111-120 of 142) with videos related to
Page
of 15
Sort By:
Cancers
|
February 15, 2022
Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program
Bastien Collomb, Amélie Dubromel, Anne Gaëlle Caffin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma
Joyce F Liu, Nicoletta Colombo, Amit M Oza, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 24, 2024
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer
Alejandro Perez-Fidalgo, Barbara Schmalfeldt, Angela George, et al.
Gynecologic Oncology
|
April 26, 2025
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial
Benoit You, Charles Anderson, Sabrina Chiara Cecere, et al.
Future Oncology (London, England)
|
January 13, 2017
EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib
Mévidette El-Madani, Olivier Colomban, Michel Tod, et al.
British Journal of Cancer
|
November 16, 2024
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer
Robert D Morgan, Xin Wang, Bethany M Barnes, et al.
British Journal of Cancer
|
April 1, 2022
Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era
Benoit You, Lilian Van Wagensveld, Michel Tod, et al.
JAMA Oncology
|
June 11, 2026
Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors: The TROPHAMET Phase 1/2 Nonrandomized Clinical Trial
Benoit You, Jean-Pierre Lotz, Pierre Descargues, et al.
Ebiomedicine
|
December 27, 2019
The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients
Benoit You, Frédéric Mercier, Eric Assenat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2022
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
Benoit You, Christopher Purdy, Larry J Copeland, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 142) with videos related to
Sort By:
Page
of 15
Cancers
|
February 15, 2022
Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program
Bastien Collomb, Amélie Dubromel, Anne Gaëlle Caffin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma
Joyce F Liu, Nicoletta Colombo, Amit M Oza, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 24, 2024
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer
Alejandro Perez-Fidalgo, Barbara Schmalfeldt, Angela George, et al.
Gynecologic Oncology
|
April 26, 2025
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial
Benoit You, Charles Anderson, Sabrina Chiara Cecere, et al.
Future Oncology (London, England)
|
January 13, 2017
EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib
Mévidette El-Madani, Olivier Colomban, Michel Tod, et al.
British Journal of Cancer
|
November 16, 2024
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer
Robert D Morgan, Xin Wang, Bethany M Barnes, et al.
British Journal of Cancer
|
April 1, 2022
Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era
Benoit You, Lilian Van Wagensveld, Michel Tod, et al.
JAMA Oncology
|
June 11, 2026
Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors: The TROPHAMET Phase 1/2 Nonrandomized Clinical Trial
Benoit You, Jean-Pierre Lotz, Pierre Descargues, et al.
Ebiomedicine
|
December 27, 2019
The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients
Benoit You, Frédéric Mercier, Eric Assenat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2022
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
Benoit You, Christopher Purdy, Larry J Copeland, et al.
Page
of 15